Artículo de revista
Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Registro en:
10.1016/j.annonc.2023.01.006
Autor
Rha, SY; Wyrwicz, LS; Weber, PEY; Bai, Y; Ryu, MH; Lee, J; Rivera, F; Alves, GV; Garrido, M; Shiu, KK; Fernandez, MG; Li, J; Lowery, M; Cil, T; Cruz, FJSM; Qin, S; Yin, L; Bordia, S; Bhagia, P; Oh, DY